Johnson & Johnson $JNJ Shares Purchased by B. Metzler seel. Sohn & Co. AG

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in Johnson & Johnson by 1.5%, now holding 442,855 shares valued at approximately $73.4 million.
• Several analysts have recently adjusted their ratings on Johnson & Johnson shares, with Bank of America increasing the target price from $161.00 to $175.00 and maintaining a "neutral" rating.
• Johnson & Johnson reported a net margin of 25% and a dividend of $1.30 per share, yielding approximately 2.9% annually.

B. Metzler seel. Sohn & Co. AG grew its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 442,855 shares of the company's stock after purchasing an additional 6,407 shares during the period. Johnson & Johnson makes up about 0.8% of B. Metzler seel. Sohn & Co. AG's holdings, making the stock its 27th largest holding. B. Metzler seel. Sohn & Co. AG's holdings in Johnson & Johnson were worth $73,443,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in JNJ. Highline Wealth Partners LLC grew its position in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $47,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Capital A Wealth Management LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $50,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson in the first quarter valued at approximately $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.7%

Shares of NYSE:JNJ traded down $1.29 during trading on Thursday, hitting $175.50. The company's stock had a trading volume of 6,423,524 shares, compared to its average volume of 8,630,407. The business has a 50 day moving average price of $165.45 and a two-hundred day moving average price of $159.86. The company has a market capitalization of $422.67 billion, a PE ratio of 18.77, a P/E/G ratio of 2.25 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the company earned $2.82 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Barclays upped their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Royal Bank Of Canada upped their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Finally, Morgan Stanley upped their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.